Abstract
Objective: In October 2018, the SOLO-1 trial showed maintenance olaparib compared to placebo had a 70% lower risk of disease progression or death among women with newly diagnosed, advanced epithelial ovarian cancer (EOC) with germline or somatic BRCA1 and BRCA2 mutation. Our study objective was to determine whether patterns of genetic and genomic testing in patients with advanced EOC at our institution changed after SOLO1 trial announcement.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
